Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1101620220330010027
Perinatology
2022 Volume.33 No. 1 p.27 ~ p.36
A Single Center Experience of Less Invasive Surfactant Administration during 6-Year
Bae Eun-Song

Shim Gyu-Hong
Abstract
Objective: The aim of this study was to evaluate the feasibility, efficacy, and safety of less invasive surfactant administration (LISA) in preterm and term infants with respiratory distress syndrome (RDS).

Methods: We retrospectively investigated preterm and term infants born at a gestational age of 25 weeks or above who were diagnosed with RDS and admitted to the neonatal intensive care unit from January 1, 2015 to December 31, 2020. Of 277 patients, 124 were administered pulmonary surfactant by LISA (LISA group), and 153 were administered by endotracheal intubation (ETT, ETT group). We compared the clinical characteristics, adverse effects, and morbidities of the 2 groups.

Results: The LISA group had lower rates of invasive mechanical ventilation (IMV) at 72 hours after birth (P<0.001) and during hospitalization (P<0.001), higher frequency of the need for a second dose of surfactant (P=0.022), lower prevalence of periventricular leukomalacia (PVL, P=0.042), longer duration of noninvasive ventilation (NIV, P=0.003), and longer duration of IMV (P=0.014) than the ETT group. There were no significant differences in reflux, bradycardia, or decreased oxygen saturation during surfactant replacement therapy. In multivariate analysis, the LISA group also had lower rates of IMV at 72 hours after birth (P<0.001; adjusted odds ratio [aOR], 0.063; 95% confidence interval [CI], 0.033-0.122) and during hospitalization (P<0.001; aOR, 0.040; 95% CI, 0.018-0.089).

Conclusion: The LISA method may reduce the exposure to IMV in infants with RDS born after 25 weeks of gestation including late preterm and term infants.
KEYWORD
Pulmonary surfactants, Respiratory distress syndrome, Noninvasive ventilation, Mechanical ventilation
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø